Results 11 to 20 of about 5,385 (167)
Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity ...
Galina Kireeva +8 more
doaj +1 more source
Background: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia.
Francisco Javier Redondo +7 more
doaj +1 more source
OBJECTIVE: To assess the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate intraperitoneal free cancer cells and to explore the feasibility of cytological cure for peritoneal carcinomatosis (PC).
Zhonghe Ji +5 more
doaj +1 more source
Background and objective Previous studies about the prognostic value of the HIPEC have yielded controversial results. Therefore, this study aims to assess the impact of HIPEC on patients with ovarian cancer.
Guyu Zhang +5 more
doaj +1 more source
Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
Background. Ovarian cancer ranks 5th in the structure of female oncological mortality in the Russian Federation, with a first-year post-diagnosis rate of almost 35%. In 75% cases, ovarian cancer is diagnosed at stages III—IV.
M. V. Zabelin +2 more
doaj +1 more source
Background Comprehensive readmission morbidity studies after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are scarce. This study aimed to investigate readmissions and in-hospital morbidity after CRS and HIPEC. Methods
Paul Dranichnikov +2 more
doaj +1 more source
Background Acute renal impairment (ARI) is a major complication after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for cancer patients with peritoneal metastases.
Chao-Yu Chen +11 more
doaj +1 more source
Objective To retrospectively analyze the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) on the progression free survival (PFS) of advanced gastric cancer (GC) and colorectal cancer (CRC).
Miao He +4 more
doaj +1 more source
Peritoneal metastasis (PM) is commonly observed in patients with colorectal cancer (CRC). The outcome of these patients is poor, with an average survival of only six months without therapy, which requires a better understanding of PM biology and new ...
Mönch Dina +11 more
doaj +1 more source
We identified GRIA2 as a critical driver of gastric cancer peritoneal metastasis through in vivo CRISPR screening. Mechanistically, GRIA2‐mediated calcium influx inhibits GSK3β and activates Wnt/β‐catenin signaling, driven by glutamate from cancer‐associated fibroblasts.
Jie Sun +13 more
wiley +1 more source

